OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP
EHA Learning Center, Antoine BONNET, 181504
A NOVEL TELOMERASE RNA COMPONENT (TERC) VARIANT IN A FAMILY WITH MACROCYTOSIS AND MILD VARIABLE CYTOPENIAS
EHA Learning Center, Claire Burney, 181515
GENERATION OF X-LINKED DYSKERATOSIS CONGENITA-LIKE HUMAN HEMATOPOIETIC STEM CELLS
EHA Learning Center, Guillermo Guenechea, 181516
STUDY OF EXTRACELLULAR VESICLES ROLES IN THE PATHOPHYSIOLOGY OF THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS DURING ECULIZUMAB TREATMENT: A PILOT PROSPECTIVE LONGITUDINAL CLINICAL STUDY
EHA Learning Center, Adeline Wannez, 181517
TELOMERE LENGTH SCREENING TRIGGERED BY CLINICAL SUSPICION FOR CLASSICAL AND/OR CRYPTIC DYSKERATOSIS CONGENITA -PROSPECTIVE RESULTS FROM THE AACHEN TELOMEROPATHY REGISTRY
EHA Learning Center, Fabian Beier, 181518
TRANSPLANTATION IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40: MORTALITY HAS NOT BEEN REDUCED IN 2010-2015.
EHA Learning Center, Sabrina Giammarco, 181519
CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM
EHA Learning Center, Deena Iskander, 181520
BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS
EHA Learning Center, Maurizio Miano, 181521
DNA METHYLATION PROFILING IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CARRYING STEREOTYPED B-CELL RECEPTORS: A DIFFERENT CELLULAR ORIGIN FOR SUBSET #2?
EHA Learning Center, SUJATA BHOI, 181531
ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY
EHA Learning Center, Andrew Rawstron, 181532
CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPRESSING THE LIGHT CHAIN IGLV3-21 HAVE A POOR PROGNOSIS INDEPENDENTLY OF HEAVY CHAIN IGHV3-21 OR THE IGHV MUTATIONAL STATUS
EHA Learning Center, Basile Stamatopoulos, 181533
DURABILITY OF RESPONSES ON CONTINUOUS THERAPY AND FOLLOWING DRUG CESSATION IN DEEP RESPONDERS WITH VENETOCLAX AND RITUXIMAB
EHA Learning Center, Mary Ann Anderson, 181534
PREDICTIVE AND PROGNOSTIC IMPACT OF GENE MUTATIONS IN THE CONTEXT OF FLUDARABINE AND CYCLOPHOSPHAMIDE (FC) WITH OR WITHOUT OFATUMUMAB TREATMENT IN PATIENTS WITH REL/REF CLL
EHA Learning Center, Eugen Tausch, 181535
RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Alexey Danilov, 181536
RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014
EHA Learning Center, Avinash Dinmohamed, 181537
A HIGH SENSITIVITY HIGH SPECIFICITY DIGITAL PCR ASSAY FOR BCR-ABL
EHA Learning Center, Franke Georg-Nikolaus, 181548
VALIDATION OF THE EUTOS LONG TERM SURVIVAL (ELTS) SCORE IN DUTCH CML-PATIENTS
EHA Learning Center, Inge G.P. Geelen, 181549
FINAL STUDY RESULTS OF DISCONTINUATION OF DASATINIB IN PATIENTS WITH CML WHO MAINTAINED DEEP MOLECULAR RESPONSE FOR LONGER THAN ONE YEAR (DADI TRIAL) AFTER THREE YEARS OF FOLLOW-UP
EHA Learning Center, Hirohisa Nakamae, 181550
ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE
EHA Learning Center, Diana Passaro, 181551
BUILDING HUMAN BONE MARROW-LIKE MODELS TO STUDY NICHE INTERACTIONS
EHA Learning Center, Richard Groen, 181552
MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS
EHA Learning Center, Cesar Nombela Arrieta, 181553
TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION
EHA Learning Center, Marvyn Koning, 181554
IMPACT ON SURVIVAL OF EARLY DETECTION OF RECURRENCE IN THE FOLLOW-UP OF HIGH RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION
EHA Learning Center, Novella Pugliese, 181564
LATER LINE DRUG TREATMENT PATTERNS OF CLASSICAL HODGKIN'S LYMPHOMA (CHL) PATIENTS IN CANADA, FRANCE, GERMANY AND THE UNITED KINGDOM
EHA Learning Center, Katherine Byrne, 181565
CHEMOTHERAPY AND RADIATION IMPROVE SURVIVAL IN EARLY STAGE CLASSICAL HODGKIN LYMPHOMA, A STATEWIDE CANCER REGISTRY ANALYSIS.
EHA Learning Center, Hayder Saeed, 181566
THE IMPACT OF TREATMENT WITH BRENTUXIMAB VEDOTIN ON OVERALL SURVIVAL OF PATIENTS WITH HODGKIN LYMPHOMA RELAPSED AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. A NATIONWIDE POPULATION BASED ANALYSIS
EHA Learning Center, Panagiotis Tsirigotis, 181567
NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
EHA Learning Center, Burhan Ferhanoglu, 181568
GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
EHA Learning Center, Valeria Spina, 181569
FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA
EHA Learning Center, Eleonora Arboscello, 181570
DECREASED MCP-1 LEVELS IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA: A CYTOKINE SIGNATURE OF IRON DEFICIENCY
EHA Learning Center, Graca Porto, 181580
FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE COMPLEX IN WOMEN WITH IRON DEFICIENCY ANEMIA - A RANDOMISED CONTROLLED TRIAL
EHA Learning Center, Garima Chaudhry, 181581
GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY
EHA Learning Center, Amit Sud, 181582
SOX11 PROMOTES TUMOR PROTECTIVE MICROENVIRONMENT INTERACTIONS IN MANTLE CELL LYMPHOMA
EHA Learning Center, Patricia Balsas, 181583
AICDA DRIVES EPIGENETIC HETEROGENEITY IN GERMINAL CENTER-DERIVED LYMPHOMAS AND ACCELERATES LYMPHOMAGENESIS
EHA Learning Center, Maria Del Pilar Dominguez Rodriguez, 181584
XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Marta Crespo, 181585
MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.
EHA Learning Center, Yosaku Watatani, 181586
GENETIC CONFIRMATION AND FINDING NOVEL MUTATIONS IN GLANZMANN THROMBASTHENIA AND VON WILLEBRAND DISEASE FAMILIES BY DIAGNOSTIC EXOME SEQUENCING
EHA Learning Center, Ye Jee Shim, 181597
HPA-3A/3A GENOTYPE IS A POSSIBLE RISK FACTOR OF SEVERE HEMORRHAGIC SYNDROME IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Irina Zotova, 181598
AN ALGORITHM TO IDENTITY CASES OF SEVERE HEMORRHAGE IN ROUTINELY COLLECTED HEALTHCARE DATA
EHA Learning Center, Aukje Kreuger, 181599
MOLECULAR MECHANISMS AND CLINICAL SIGNIFICANCE OF REDUCED PTPN1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Masayuki SHISEKI, 181600
MOLECULAR MARKERS PREDICTING RESPONSE TO AZACITIDINE TREATMENT FOR MYELODYSPLASTIC SYNDROMES.
EHA Learning Center, Yasuhito Nannya, 181601
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Guillermo Montalban-Bravo, 181602
AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.
EHA Learning Center, Félix López Cadenas, 181603
MULTILAYER EPIGENOMIC ANALYSES REVEAL OF NEW CANDIDATE ONCOGENES INVOLVED IN THE PATHOGENESIS OF MULTIPLE MYELOMA
EHA Learning Center, Raquel Ordoñez, 181612
CLINICAL IMPLICATIONS OF CLONAL CD34+ CELLS IN STEM CELL HARVEST FROM PATIENTS WITH PLASMA CELL DYSCRASIAS
EHA Learning Center, Sneha CHITRE, 181613
PATHOPHYSIOLOGICAL FUNCTIONS AND CLINICAL IMPACT OF THE NEW IMMUNORECEPTOR SLAMF3 IN MULTIPLE MYELOMA
EHA Learning Center, Mariko Ishibashi, 181614
TARGETING CD74 IN MULTIPLE MYELOMA WITH A NOVEL ANTIBODY DRUG CONJUGATE (ADC), STRO-001
EHA Learning Center, Arturo Molina, 181615
GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING
EHA Learning Center, Isabel Cuenca, 181616
IMPROVED SURVIVAL IN 21,465 MULTIPLE MYELOMA PATIENTS: RESULTS FROM A POPULATION-BASED STUDY
EHA Learning Center, Sigrun Thorsteinsdottir, 181617
PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Moritz Binder, 181618
THE EUROPEAN MYELOMA NETWORK EMN09 STUDY: CARFILZOMIB, BENDAMUSTINE, AND DEXAMETHASONE (CBD) IS EFFICIENT AND SAFE IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
EHA Learning Center, M. Gramatzki, 181628
CHEMOTHERAPY BEFORE AND AFTER HEART TRANSPLANTATION FOR PATIENTS WITH ADVANCED CARDIAC AL AMYLOIDOSIS, SINGLE CENTER RESULTS WITH LONG-TERM FOLLOW-UP
EHA Learning Center, Ute Hegenbart, 181629
MM-013 PHASE 2 MULTICENTER STUDY OF POMALIDOMIDE (POM) PLUS LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)
EHA Learning Center, Pieter Sonneveld, 181630
PEMBROLIZUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B KEYNOTE-013 STUDY
EHA Learning Center, David Siegel, 181631
ASSESSMENT OF MOBILIZATION COST FOR MULTIPLE MYELOMA USING 2 DIFFERENT STRATEGIES: HIGH-DOSE CYCLOPHOSPHAMIDE VERSUS PLERIXAFOR. ON BEHALF OF IFM.
EHA Learning Center, Zoe Van de Wyngaert, 181632
SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF INDUCTION TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Jinchul Kim, 181633
A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK
EHA Learning Center, Ovini GAMAGE, 181634
CLINICAL PHENOTYPE AND OUTCOME OF ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC MYELOFIBROSIS DIAGNOSED ACCORDING TO THE REVISED 2016 WHO DIAGNOSTIC CRITERIA
EHA Learning Center, Michele Ciboddo, 181644
VALIDATION OF THE REVISED IPSET-THROMBOSIS SCORE IN 734 PATIENTS WITH WHO 2016-DEFINED ESSENTIAL THROMBOCYTHEMIA. REPORT OF THE REGISTRO ITALIANO TROMBOCITEMIE (RIT)
EHA Learning Center, Luigi Gugliotta, 181645
CORRELATIONS BETWEEN INFLAMMATORY BIOMARKERS AND INDIVIDUAL SYMPTOMS EXPRESSED BY MYELOFIBROSIS PATIENTS IN THE COMFORT-I TRIAL: ANALYSIS OF BASELINE ASSOCIATIONS AND CHANGES OVER TIME
EHA Learning Center, Holly L Geyer, 181646
NOVEL HETEROZYGOUS ITGB3 P.T746DEL MUTATION INDUCING SPONTANEOUS ACTIVATION OF INTEGRIN ΑIIBΒ3 CAUSES AUTOSOMAL DOMINANT MACROTHROMBOCYTOPENIA WITH ABNORMAL ΑIIBΒ3 LOCALIZATION
EHA Learning Center, Naohiro Miyashita, 181647
CHANGES IN THE GENE EXPRESSION PROFILE OF IMMUNE THROMBOCYTOPENIA PATIENTS TREATED WITH ELTROMBOPAG
EHA Learning Center, Jose Maria Bastida Bermejo, 181648
DEFECTIVE PTEN REGULATION CONTRIBUTES TO B CELL HYPERRESPONSIVENESS IN CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Shixuan wang, 181649
ACCESS TO COMMUNITY CHEMOTHERAPY IMPROVES PATIENT QUALITY OF LIFE
EHA Learning Center, Wendy Ingram, 181661
THE BUDGET IMPACT OF TREATMENT-FREE REMISSION FOR FIRST-LINE NILOTINIB OR GENERIC IMATINIB IN TREATING CHRONIC PHASE PHILADELPHIA-POSITIVE CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Patricia Brandt, 181662
GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (>65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Javier De La Rubia, 181663
NUTRITIONAL NEEDS AND PREFERENCES OF MYELOPROLIFERATIVE NEOPLASM PATIENTS: PHASE IA OF THE NUTRIENT STUDY
EHA Learning Center, Robyn , 181664
DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE
EHA Learning Center, Aliki XOCHELLI, 181665
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Jonathan Canaani, 181666
QUANTITATIVE PROTEOMICS OF PLASMA EXTRACELLULAR VESICLES TO IDENTIFY NOVEL BIOMARKERS OF CLINICAL SEVERITY FOR HBE/Β-THALASSEMIC PATIENTS
EHA Learning Center, Janejira Kittivorapart, 181678
A SELECTIVE ORAL GLYT1 INHIBITOR IMPROVES ANEMIA IN A MOUSE MODEL OF BETA-THALASSEMIA
EHA Learning Center, Lucia de Franceschi, 181679
MAY MUTATIONS IN THE KLF1 GENE HAVE WORSENING EFFECTS ON THE BETA THALASSEMIA PHENOTYPE?
EHA Learning Center, Michela Grosso, 181680
SECONDARY SOLID TUMORS FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION FOR THALASSEMIA MAJOR
EHA Learning Center, Antonella Meloni, 181681
VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES
EHA Learning Center, thidarat suksangpleng, 181682
TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING LIVER FIBROSIS
EHA Learning Center, Alessia Marcon, 181683
IKZF1Δ4-7 CAN BE EASILY SCREENED BY PCR BUT DOES NOT PREDICT OUTCOME IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA; DATA FROM 490 PATIENTS ENROLLED ON THE UKALL14 TRIAL.
EHA Learning Center, Rachel Mitchell, 181447
PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE DETECTED BY MLL FUSION GENE TRANSCRIPTS IN INFANT ACUTE LYMPHOBLASTIC LEUKEMIA. UPDATED RESULTS OF 76 PATIENTS ENROLLED INTO MLL-BABY STUDY
EHA Learning Center, Grigory Tsaur, 181448
PRO-T CELL ALL/LBL: AN ULTRA-HIGH RISK CD2-NEGATIVE DISEASE SUBTYPE IN ADULTS DEFINED BY FLOW CYTOMETRY
EHA Learning Center, Beata Ostrowska, 181449
CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE
EHA Learning Center, Renato Bassan, 181450
RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Nick Morley, 181451
CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Kevin Miller, 181452
THE PMLC62A/C65A KNOCK-IN MOUSE MODEL PROVIDES EVIDENCE FOR THE ROLE OF NUCLEAR BODY DISRUPTION IN THE PATHOGENESIS OF ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Edwige VOISSET, 181463
DECIPHERING THE ONCOGENIC NETWORK OF PRC2 LOSS GUIDED LEUKEMOGENISIS
EHA Learning Center, Jan-Henning Klusman, 181464
ACUTE MYELOID LEUKEMIA EVOLUTION CAN BE RECONSTRUCTED BY ANALYSIS OF NON-LEUKEMIC CELLULAR SUBCOMPARTMENTS AND MULTI-LINEAGE ENGRAFTED MICE
EHA Learning Center, Borhan Saeed, 181466
THE ESSENTIAL ROLE OF THE ENHANCERS OF POLYCOMB EPC1 AND EPC2 IN MLL-AF9 ACUTE MYELOID LEUKAEMIA IS A ‘COMPLEX' STORY
EHA Learning Center, Niamh Mannion, 181467
STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX
EHA Learning Center, Riikka Karjalainen, 181468
IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING
EHA Learning Center, Frank Rücker, 181469
DO EDUCATION AND INCOME AFFECT TREATMENT AND OUTCOME IN ACUTE MYELOID LEUKEMIA IN A TAX-SUPPORTED HEALTH CARE SYSTEM? A DANISH NATIONAL POPULATION-BASED COHORT STUDY
EHA Learning Center, lene granfeldt, 181480
IDENTIFICATION OF PATTERNS IN CO-OCCURRING MUTATIONS IN AML PATIENTS WITH GERMLINE AND SOMATIC RUNX1 MUTATIONS
EHA Learning Center, Uma Borate, 181481
MULTIPLE LEUKEMIC STEM CELL MARKER EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN DE NOVO ACUTE MYELOID LEUKEMIA
EHA Learning Center, Tomohiro Yabushita, 181483
NEXT GENERATION SEQUENCING TARGETED PANEL FOR MINIMAL RESIDUAL DISEASEMONITORING IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Valerie McClain, 181484
IS IT POSSIBLE TO RELIABLY DETECT CLINICALLY-RELEVANT BIALLELIC CEBPA GENE MUTATIONS USING NGS PANELS?
EHA Learning Center, Marta Fernandez-Mercado, 181485
EXPERIENCE WITH MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN AML WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS
EHA Learning Center, Alexander Höllein, 181486
NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Guillermo Montalban-Bravo, 181487
OVERALL SURVIVAL AND TRANSPLANTATION IN PATIENTS WITH FLT3 MUTATIONS: SUBGROUP ANALYSIS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Bruno Medeiros, 181497
NIVOLUMAB MAINTENANCE THERAPY FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML) IN REMISSION
EHA Learning Center, Tapan Kadia, 181498
HIGHER EXPRESSION OF LONG NON-CODING RNA KIAA0125 IS ASSOCIATED WITH CHARACTERISTIC CLINICAL AND BIOLOGICAL FEATURES AND IS AN INDEPENDENT POOR PROGNOSTIC FACTOR IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Sheng-Yu Hung, 181499
LEUKEMIC STEM CELLS CAN BE DETECTED IN A CONSIDERABLE PERCENTAGE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AT DIAGNOSIS AND IS A SIGNIFICANT PROGNOSTIC FACTOR
EHA Learning Center, Olga Pérez-López, 181500
POST-REMISSIONAL AND PRE-TRANSPLANT ROLE OF MINIMAL RESIDUAL DISEASE DETECTED BY WT1 IN ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COHORT STUDY
EHA Learning Center, Chiara Frairia, 181501
DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)
EHA Learning Center, Amir T. Fathi, 181502